Goldman Sachs Raises Price Target to $199, Marsh & McLennan to Rebrand as MRSH

MMCMMC

Goldman Sachs kept a Neutral rating on Marsh & McLennan, raising its price target to $199 from $196 and noting the company's rebranding to MRSH on January 14, 2026. Shares dipped 1.42% to $182.90, with a market cap near $90B and a Q4 earnings call set for January 29.

1. Robust Financial Performance

Marsh & McLennan has delivered consistent growth over the past decade, with revenue compounding at an annual rate of 9% and net income expanding by 15.4% per year. The company’s diversified portfolio across risk management, insurance broking, consulting and talent solutions has enabled it to leverage its scale and global brand to win large client mandates. During the latest fiscal year, Marsh & McLennan reduced its share count by more than 3%, reflecting ongoing share repurchase programs that complement its strong free cash flow generation.

2. Valuation Discount Offers Entry Opportunity

Despite its long track record of predictable earnings expansion, Marsh & McLennan currently trades at approximately 3.5 times trailing revenues and 22.4 times trailing earnings, a discount to its five-year historical range. This valuation gap partly reflects cyclical pressures in broader commercial insurance rate renewals, which have weighed on near-term top-line growth expectations. For long-term investors, the combination of resilient margins in its consulting businesses and a durable capital return framework creates an attractive entry point relative to peers.

3. Strategic Rebranding and Ticker Change

As part of a broader initiative to align its identity with core capabilities, Marsh & McLennan will update its trading symbol to MRSH on January 14, 2026. The move is designed to emphasize the company’s focus on risk, strategy and people management solutions while maintaining continuity for shareholders. No action is required from existing investors, and operational reporting and client engagement processes will continue uninterrupted under the new symbol.

4. Analyst Outlook and Ratings

Goldman Sachs has maintained a Neutral recommendation on Marsh & McLennan, citing a balanced risk-reward profile given near-term insurance cycle headwinds against a strong compounder track record. The firm recently increased its 12-month target, reflecting confidence in the firm’s ability to sustain margin expansion in consulting and talent management. Investor focus now turns to the upcoming fourth-quarter earnings call, where management is expected to provide updates on renewal rate trends and capital deployment plans.

Sources

FS